Zealand Pharma Loses Fifth of Value After Trial Dropouts
Danish biotech Zealand Pharma saw its stock slide after disclosing a 20% dropout rate in its weight-loss drug trial d...
Different volatility measures reveal different risk facets of stock indices. This primer clarifies what each metric means for decisions.
23,218 articlesDanish biotech Zealand Pharma saw its stock slide after disclosing a 20% dropout rate in its weight-loss drug trial d...
Japan is advancing legislation to regulate crypto like stocks, aiming to lower taxes and unlock regulated crypto ETFs...
The latest U.S. limits on Anthropic’s Fable open the door for open-source AI, lifting demand for cheaper, self-hosted...
A $1 million horror film defies expectations while a 30-year-old franchise returns with a bold new installment, deliv...
The space economy is heating up, and a few standout names could reshape portfolios. This article breaks down the best...
VYM has posted strong long-term gains, delivering around 200% over 10 years. Yet its income yield lags behind more in...
A doctored AI image sparked laughter and questions about authenticity. This piece uses the moment to teach practical ...
Broadcom is moving deeper into AI infrastructure, signaling a shift that could influence chip design, data-center cos...
Morgan Stanley's latest bottom up view argues that AI infrastructure demand will outpace supply, turning the Nebius s...
A booming demand backdrop for chips collides with sky-high spending. This piece breaks down what Taiwan Semiconductor...
CoreWeave sits at the intersection of explosive AI demand and a looming debt challenge. A multi-billion backlog canno...
A U.S. equity ETF with about $11 billion in assets is beating the broad market by favoring profitable, attractively v...